Chengdu Olymvax Biopharmaceuticals, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Operating Profit of 296.87%, the company declared Very Positive results in Mar 25

The company has declared positive results for the last 2 consecutive quarters
OPERATING CASH FLOW(Y) Highest at CNY 33.06 MM
NET PROFIT(HY) At CNY 9.66 MM has Grown at 124.94%
NET SALES(HY) At CNY 287.7 MM has Grown at 35.08%

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 7,598 Million (Large Cap)

P/E

127.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.20

Return on Equity

6.45%

Price to Book

8.21

Revenue and Profits:

Net Sales:

216 Million

(Quarterly Results - Jun 2025)

Net Profit:

20 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-5.45%

6 Months

55.08%

1 Year

125.85%

2 Years

57.69%

3 Years

74.76%

4 Years

-22.22%

5 Years

0.0%

Chengdu Olymvax Biopharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

18.20%

EBIT Growth (5y)

-1.90%

EBIT to Interest (avg)

15.30

Debt to EBITDA (avg)

0.61

Net Debt to Equity (avg)

0.18

Sales to Capital Employed (avg)

0.46

Tax Ratio

15.47%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.29%

ROE (avg)

4.40%

Valuation key factors

Factor

Value

P/E Ratio

127

Industry P/E

Price to Book Value

8.21

EV to EBIT

120.29

EV to EBITDA

75.29

EV to Capital Employed

6.99

EV to Sales

11.73

PEG Ratio

0.55

Dividend Yield

ROCE (Latest)

5.81%

ROE (Latest)

6.45%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 40.25% vs -6.48% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 697.06% vs -114.11% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "216.40",
          "val2": "154.30",
          "chgp": "40.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "32.20",
          "val2": "6.90",
          "chgp": "366.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.70",
          "val2": "3.60",
          "chgp": "2.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "20.30",
          "val2": "-3.40",
          "chgp": "697.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "101.90%",
          "val2": "-12.50%",
          "chgp": "11.44%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 18.73% vs -9.40% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 37.72% vs -57.14% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "585.10",
          "val2": "492.80",
          "chgp": "18.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "57.40",
          "val2": "37.60",
          "chgp": "52.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "14.50",
          "val2": "7.20",
          "chgp": "101.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "15.70",
          "val2": "11.40",
          "chgp": "37.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.60%",
          "val2": "7.40%",
          "chgp": "2.92%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

216.40

154.30

40.25%

Operating Profit (PBDIT) excl Other Income

32.20

6.90

366.67%

Interest

3.70

3.60

2.78%

Exceptional Items

0.00

Consolidate Net Profit

20.30

-3.40

697.06%

Operating Profit Margin (Excl OI)

101.90%

-12.50%

11.44%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 40.25% vs -6.48% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 697.06% vs -114.11% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

585.10

492.80

18.73%

Operating Profit (PBDIT) excl Other Income

57.40

37.60

52.66%

Interest

14.50

7.20

101.39%

Exceptional Items

0.00

Consolidate Net Profit

15.70

11.40

37.72%

Operating Profit Margin (Excl OI)

36.60%

7.40%

2.92%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 18.73% vs -9.40% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 37.72% vs -57.14% in Dec 2023

All Annual Results

Company CV

About Chengdu Olymvax Biopharmaceuticals, Inc.

Chengdu Olymvax Biopharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available